AKTS logo

AKTSAkoustis Technologies Inc

$18.87
$1.02
(5.13%)
Today
Closed $18.87
$0.37
(1.96%)
After Hours
Updated: 04:57 PM EDT
Reported EarningsMay 11
Mkt Cap$1.05B
Vol138,620.00
News
all
press releases
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate...
MarketBeat
News Placeholder
More News
News Placeholder
Aktis Oncology (AKTS) Expected to Announce Earnings on Friday
Aktis Oncology (NASDAQ:AKTS) will be releasing its Q1 2026 earnings on Friday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-8-akoustis-technologies-inc-stock...
MarketBeat
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - What's Next?
Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - Time to Sell...
MarketBeat
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?
Aktis Oncology (NASDAQ:AKTS) Stock Crosses Above Fifty Day Moving Average - Time to Sell...
MarketBeat
News Placeholder
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% - Here's Why
Aktis Oncology (NASDAQ:AKTS) Stock Price Down 3.7% - Time to Sell...
MarketBeat
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of "Buy" from Analysts
Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five...
MarketBeat
News Placeholder
Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright
Aktis Oncology (NASDAQ:AKTS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a research report issued to clients...
MarketBeat
News Placeholder
HC Wainwright Comments on Aktis Oncology Q1 Earnings
Aktis Oncology (NASDAQ:AKTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a research note issued on Tuesday, March 31st. HC...
MarketBeat
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright
HC Wainwright boosted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a report on Tuesday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.